The findings of the study challenge concerns that exposure therapy may worsen symptoms in patients with PTSD, particularly when comorbid SUD is present.
Researchers tested for continuous measures of trauma-related dissociation using the Multidimensional Inventory of Dissociation. Connectivity estimates were derived with a novel machine learning technique using individually defined homologous functional regions for each participant.
The prevalence of acute posttraumatic stress symptoms in the study population was 4.6%, ranging from 4.4% in healthcare workers to 518.4% in the high-risk general population.
The Food and Drug Administration (FDA) has granted Fast Track designation to BNC210 (Bionomics Limited) for the treatment of post-traumatic stress disorder (PTSD) and other trauma-related and stressor-related disorders.
Among patients who received stellate ganglion block (n=74), the adjusted mean CAP-5 total symptom severity score change from baseline was -12.6 points (95% CI, -15.5, -9.7 points) vs -6.1 points (95% CI, -9.8, -2.3 points) for those who received sham treatment.
The long-term benefits of pharmacologic treatments were inferior to those of psychotherapeutic and combined treatments across 6 randomized clinical trials reviewed by investigators.
A machine learning algorithm trained on electroencephalographic coherence can predict transcranial magnetic stimulation treatment outcome for patients with major depressive disorder and posttraumatic stress disorder.
